Company stock · NASDAQ · USD

NTLA

Intellia Therapeutics Inc

$11.21

Today

+$0.05+0.45%

vs yesterday’s close

Live price

Opened at: $11.00
Day high: $11.24
Day low: $10.58
Yesterday’s close: $11.16

Sector: Healthcare
Industry: Biotechnology
Size: Medium-sized company
Market value: $1.6 billion
Number of shares: 140.1 million
Country: US
Went public: May 6, 2016
Exchange: NASDAQ
Website: intelliatx.com
Next earnings: 2026-11-05 · analysts’ expected profit per share $-0.81

Themes

Healthcare innovation

Compare →Earnings calendar →

Price chart Pro

Loading chart…

Company briefing

What NTLA is

Plain English context — why the name shows up in the news, and what to watch next.

In plain English

Intellia Therapeutics Inc. develops CRISPR‑based gene‑editing medicines aimed at treating genetic diseases. The company is a mid‑cap…

Recent headlines

Live company news for NTLA — each headline includes a ClearTape brief in plain English; open the original for the full story.

The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking TherapeuticsIn brief
BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics are pushing late‑stage drug pipelines, with upcoming regulatory decisions and clinical trial results. The focus is on how these developments could impact their future prospects.
Yahoo · Oct 21, 2026
Intellia Therapeutics (NTLA) Stock Looks Overvalued As Launch Preparations AdvanceIn brief
Intellia Therapeutics’ stock has dropped sharply over the past years, even as the company moves closer to commercializing gene‑editing therapies. Investors are questioning whether the current price reflects the company’s revenue base.
Yahoo · Oct 18, 2026
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical OfficerIn brief
CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr.
Yahoo · Oct 13, 2026
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?In brief
Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Yahoo · Oct 9, 2026
Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8In brief
Barclays has started covering Intellia Therapeutics, giving it an Underweight rating and setting a price target of $8 per share.
Benzinga · Oct 6, 2026
Intellia Therapeutics Q2 2026 Earnings Call TranscriptIn brief
Intellia Therapeutics (NASDAQ:NTLA) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call
Benzinga · Oct 5, 2026

Same sector

Similar companies · Healthcare

% is today vs yesterday’s close

Latest on this name

Insights & deeper context

Cards about this company show up here when there is news.

No insights yet

Search another name, add NTLA to your watchlist, or check back when fresh news hits. If this company also trades in the US, the “Same company” link above opens that listing.

Back to feed →

Company reports

Official filings (US SEC and linked cards)

No filings here yet

Official report cards for NTLA will show up here when available.

Broad market indexes (like the S&P 500, a basket of 500 large US companies) are shown through popular funds that track them (for example SPY). Company profile and prices use live market data when available.